Emergent BioSolutions has unveiled plans to strengthen its contract development and manufacturing (CDMO) capabilities by expanding into viral vector and gene therapy. The company will invest $75 million in its Canton, MA facility, which is focused on the development and manufacturing of drug substance for live viral vaccines, including the company’s smallpox vaccine.
{iframe}https://www.contractpharma.com/contents/view_breaking-news/2020-06-18/emergent-biosolutions-enters-viral-vector-and-gene-therapy-arena/{/iframe}